Skip to main content
Premium Trial:

Request an Annual Quote

Helomics Completes Restructuring to Clinical CRO

NEW YORK (GenomeWeb) – Helomics said today that it has completed the final phase of a restructuring process designed to establish the company as a clinical contract research and clinical products organization.

The Pittsburgh-based company will now provide product enhancement and clinical laboratory services — including comprehensive tumor profiling using proprietary cell-based products and services — to customers in the healthcare industries. Patients who consent to undergo sample testing at Helomics have the opportunity to further cancer research and the development of new therapies and diagnostics through Helomics' technology development and industry partnerships, the firm added.

Gerald Vardzel, Jr. will serve as president and CEO of the company, replacing Neil Campbell, who is no longer with the firm. Campbell had joined the firm in late 2014, around the time the company changed its name to Helomics from Precision Therapeutics.

Helomics made the announcement a week after the Pittsburgh Post-Gazette reported that a group of investors, including Vardzel, had acquired the firm from Stamford, Connecticut-based healthcare investment firm HealthCare Royalty Partners. The company did not disclose financial details of the acquisition.

In February, Helomics launched two new servicesan expansion of its live-cell analysis platform called CellFx, and a tumor shedding analysis called Defender that is intended to serve as a virtual parallel to liquid biopsies.

These services are part of the company's comprehensive tumor profiling offering. Helomics also offers two genetic tests for disease recurrence: GeneFx Colon, a microarray-based test for stage II colon cancer patients; and GeneFx Lung, an array-based 15-gene assay, licensed from Almac Diagnostics and Med BioGene, respectively.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.